Skip to content

Clinical efficacy and safety of urokinase in the treatment of progressive ischemic stroke: a randomized controlled trial

Clinical efficacy and safety of urokinase in the treatment of progressive ischemic stroke: a randomized controlled trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100046384
Enrollment
Unknown
Registered
2021-05-15
Start date
2021-05-15
Completion date
Unknown
Last updated
2021-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

progressive ischemic stroke

Interventions

Experimental group:Intravenous infusion of urokinase
Control group:Routine treatment of acute cerebral infarction

Sponsors

Shandong Provincial Qianfoshan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Comply with "China Acute Ischemic Stroke Treatment Guide 2018" acute ischemic stroke diagnosis standard; 2. TOAST layout is a large atherosclerosis; 3. Baseline NIHSS score <= 15 points (ie light among stroke); 4. In line with the diagnostic criteria for progressive ischemic stroke, has progressed in 72 hours after the stroke, and the NiHSS score increased by 2 points; 5. Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Aged 70 years; 2. Thrombolysis or mechanical thrombectomy within the time window; 3. The time of onset is not clear; 4. Pregnancy; 5. Accompanied by epileptic seizures at the onset; 6. A history of cerebral infarction or a history of severe brain injury within 3 months before the onset; 7. Severe infarction (infarction in the blood supply area of more than 1/3 of the middle cerebral artery in imaging); 8. Take heparin within 48 hours before the onset of the stroke, and the activated partial thromboplastin time exceeds the upper limit of the normal range at the time of the onset (the normal range of partial thromboplastin time in our hospital: 22.7-31.8 seconds); 9. The platelet count is lower than 100 x 10^9/L; 10. Systolic blood pressure>185mmHg or diastolic blood pressure>110mmHg or blood pressure requires active treatment to reduce blood pressure to these limits; 11. Blood sugar is lower than 2.8mmol/L or higher than 22.2mmol/L; 12. Suspicious symptoms of subarachnoid hemorrhage, even if the brain CT shows normal; 13. There is a history of major surgery or severe trauma three months before the onset of illness; 14. Past history of intracranial hemorrhage; 15. Have gastrointestinal bleeding or urinary tract bleeding in the past 21 days; 16. Perform arterial puncture at a non-compressible site within the first 7 days; 17. Taking anticoagulant or receiving heparin treatment within 48 hours before the onset of stroke and the partial thromboplastin time is prolonged; 18. The prothrombin time is greater than 15 seconds; 19. Mild symptoms or rapid improvement; 20. Patients with poor general conditions, such as severe electrolyte imbalance, failure of important organs such as heart, liver and kidney, severe infection, deep coma on admission or unstable vital signs.

Design outcomes

Primary

MeasureTime frame
NIH Stroke Scale;Brain CT / MRI;Mortality;

Secondary

MeasureTime frame
Modified Rankin Scale;

Countries

China

Contacts

Public ContactLi Yanbin

Shandong Provincial Qianfoshan Hospital

13864006933@163.com+86 13864006933

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026